Conference Coverage
Conference Coverage
Drug can prevent bleeding in hemophilia A and B
ORLANDO—Results from an ongoing phase 1 study suggest fitusiran, a small interfering RNA therapeutic targeting antithrombin (AT), can restore...
Conference Coverage
Testosterone might counteract chemotherapy heart damage
Key clinical point: Adjunct testosterone improved cardiac function in head, neck, and cervical cancer patients undergoing standard treatment in a...
Conference Coverage
Gene therapy reduces need for FIX prophylaxis
Image courtesy of NIGMS ORLANDO—The gene therapy AMT-060 can reduce the need for factor IX (FIX) prophylaxis in patients with severe hemophilia B...
Conference Coverage
Gene therapy shows promise for severe hemophilia A
Image by Spencer Phillips ORLANDO—An investigational gene therapy can safely reduce bleeding in patients with severe hemophilia A, a phase 1/2...
Conference Coverage
Certain skin cancers respond to nonsurgical treatments
Conference Coverage
How hemophilia B impacts education, work
ORLANDO—Even mild or moderate hemophilia B can have a negative impact on the education and careers of patients, according to the B-HERO-S study....
Conference Coverage
mAb could change treatment of hemophilia A, doc says
Photo by Linda Bartlett ORLANDO—Emicizumab, a bispecific monoclonal antibody (mAb), could potentially change the treatment paradigm of hemophilia...
Conference Coverage
Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
Key clinical point: A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A...
Conference Coverage
CAR T-cell therapy eyed for CLL patients with residual disease
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy....
Conference Coverage
Therapy seems safe, effective in kids with hemophilia
Photo courtesy of Baxalta ORLANDO—Results of a phase 3 study suggest the full-length recombinant factor VIII therapy Adynovate (BAX 855) can be...
Conference Coverage
Patients can safely receive less FVIII, study suggests
ORLANDO—It may be possible for hemophilia patients to receive less factor VIII (FVIII) without increasing their risk of bleeding, according to a...